Literature DB >> 17541329

Coronary heart disease events preventable by control of blood pressure and lipids in US adults with hypertension.

Victor A Lopez1, Stanley S Franklin, Simon Tang, Nathan D Wong.   

Abstract

Hypertension (HTN) and dyslipidemia are major risk factors for coronary heart disease (CHD). In 676 (projected to 26.1 million) US persons from the National Health and Nutrition Examination Survey (NHANES) 2001-2002 with HTN, the authors estimated the preventable CHD events from statistical control of blood pressure (BP) and lipid levels. Using Framingham algorithms, the authors projected the CHD events that could be prevented from statistical control of BP, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol. If BP was controlled to nominal levels, the authors projected 19% of CHD events (37% if controlled to optimal) would be prevented. Improving lipid levels to nominal levels was estimated to prevent 27% of CHD events (62% if controlled to optimal). Combined control of BP and lipid levels to nominal levels was projected to prevent 38% of CHD events (76% if controlled to optimal). The authors' results demonstrate that combined control of BP and lipid levels may prevent the majority of CHD events in Americans with HTN.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541329      PMCID: PMC8110009          DOI: 10.1111/j.1524-6175.2007.06518.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  12 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Therapeutic goal attainment in patients with hypertension and dyslipidemia.

Authors:  Michael L Johnson; Kenneth Pietz; David S Battleman; Rebecca J Beyth
Journal:  Med Care       Date:  2006-01       Impact factor: 2.983

3.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.

Authors:  B G Brown; X Q Zhao; A Chait; L D Fisher; M C Cheung; J S Morse; A A Dowdy; E K Marino; E L Bolson; P Alaupovic; J Frohlich; J J Albers
Journal:  N Engl J Med       Date:  2001-11-29       Impact factor: 91.245

4.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

5.  Prevalence, treatment, and control of combined hypertension and hypercholesterolemia in the United States.

Authors:  Nathan D Wong; Victor Lopez; Simon Tang; G Rhys Williams
Journal:  Am J Cardiol       Date:  2006-05-11       Impact factor: 2.778

6.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.

Authors:  G Brown; J J Albers; L D Fisher; S M Schaefer; J T Lin; C Kaplan; X Q Zhao; B D Bisson; V F Fitzpatrick; H T Dodge
Journal:  N Engl J Med       Date:  1990-11-08       Impact factor: 91.245

Review 7.  Evidence for a combined approach to the management of hypertension and dyslipidemia.

Authors:  Benjamin J Ansell
Journal:  Am J Hypertens       Date:  2005-09       Impact factor: 2.689

Review 8.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

Authors:  Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone
Journal:  Circulation       Date:  2004-07-13       Impact factor: 29.690

9.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

Authors:  Ihab Hajjar; Theodore A Kotchen
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

10.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

View more
  6 in total

1.  Combined association of lipids and blood pressure in relation to incident cardiovascular disease in the elderly: the cardiovascular health study.

Authors:  Nathan D Wong; Victor A Lopez; Craig S Roberts; Henry A Solomon; Gregory L Burke; Lewis Kuller; Russell Tracy; David Yanez; Bruce M Psaty
Journal:  Am J Hypertens       Date:  2009-11-19       Impact factor: 2.689

2.  The newly identified hypertensive patient: cost-effective laboratory investigation.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-01       Impact factor: 3.738

3.  Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension.

Authors:  Menco G Niemeijer; Ton J Cleophas
Journal:  Pharmaceuticals (Basel)       Date:  2009-12-01

4.  Blood pressure and low-density lipoprotein cholesterol control status in Chinese hypertensive dyslipidemia patients during lipid-lowering therapy.

Authors:  Xiaowei Yan; Yong Li; Yugang Dong; Yanhua Wu; Jihu Li; Rui Bian; Dayi Hu
Journal:  Lipids Health Dis       Date:  2019-01-29       Impact factor: 3.876

5.  Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.

Authors:  Bimal V Patel; R Scott Leslie; Patrick Thiebaud; Michael B Nichol; Simon S K Tang; Henry Solomon; Dennis Honda; JoAnne M Foody
Journal:  Vasc Health Risk Manag       Date:  2008

6.  Reducing the Blood Pressure-Related Burden of Cardiovascular Disease: Impact of Achievable Improvements in Blood Pressure Prevention and Control.

Authors:  Shakia T Hardy; Laura R Loehr; Kenneth R Butler; Sujatro Chakladar; Patricia P Chang; Aaron R Folsom; Gerardo Heiss; Richard F MacLehose; Kunihiro Matsushita; Christy L Avery
Journal:  J Am Heart Assoc       Date:  2015-10-27       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.